The Pharma R&D Fact Book 2006 - Biologics Market Research

The Pharma R&D Fact Book 2006
Espicom Healthcare Intelligence
August 24, 2006
578 Pages
Pub ID: ESPI1331466
$995.00 Online DownloadUS
$995.00 Hard Copy Mail Delivery
Abstract
Countries covered: Global
Utilising daily-updated data and primary source information, plus an extensive new review of R&D investment for over 35 leading companies, the 500-page report provides a wealth of essential information.
Few pharma issues occupy as much executive and analyst time as the productivity of the industry?s research and development effort. Many forecast the impending doom of the ethical industry as we know it, citing the imbalance of patent expiries against new product launches, the absence of any real recent blockbusters and the rise of generic competition.
But what is the real situation?
How are levels of investment holding up?
How might they develop in the future?
What is the status, by development phase, of companies? R&D pipelines?
Which companies are committing most funds to their R&D effort?
Executives need current and independent information to answer these and similar questions. That is why Espicom - the leading provider of pharmaceutical competitive intelligence - has published a completely updated edition of The Pharma R&D Fact Book 2006.
Utilising daily-updated data and primary source information, the report provides an thorough examination of R&D investment for 38 leading companies. The 500-page report contains a wealth of essential information including:
At-a-glance bullet point summaries of key business facts and events for each company
Extensive analysis of R&D investment, with forecasts to 2010
Analysis of investment by US, European and Japanese companies
Research ratios by company, region and 10-year change. Dating back to 1996 with forecasts to 2010. Company-by-company graphs showing their performance against the industry average
Pipeline table and graphs for each company showing the numbers of compounds in development by stage, split by novel compounds, new indications and new formulations
Extensive monographs of each company?s pipeline showing key data such as development status, and licensing.